Clearside Biomedical

Clearside Biomedical Share Buybacks

Delisted

The Share Buybacks of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 13.91 M USD. In the previous year, Share Buybacks was 98,000.00 USD — a change of 14,090.82% (higher).

Share Buybacks

13.91 MUSD

YoY

14,090.82%

Last updated:

Share Buybacks of Clearside Biomedical is 2024 13.91 M USD. Share Buybacks of Clearside Biomedical was 2023 98,000.00 USD. It decreases by 14,090.82% higher compared to the previous year.

The Clearside Biomedical Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2017
5.36 M USD
Jan 1, 2018
80.08 M USD
Jan 1, 2019
13.70 M USD
Jan 1, 2020
12.22 M USD
Jan 1, 2021
23.78 M USD
Jan 1, 2022
700,000.00 USD
Jan 1, 2023
98,000.00 USD
Jan 1, 2024
13.91 M USD
The Clearside Biomedical Share Buybacks history
YEARShare BuybacksYoY
13.91 MUSD+14,090.82%
98,000.00USD-86.00%
700,000.00USD-97.06%
23.78 MUSD+94.60%
12.22 MUSD-10.80%
13.70 MUSD-82.89%
80.08 MUSD+1,394.03%
5.36 MUSD-93.68%
84.86 MUSD+324.94%
19.97 MUSD+56.63%
12.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

Share Buybacks of Clearside Biomedical is 13.91 M USD in 2024.

Share Buybacks of Clearside Biomedical changed from 98,000.00 USD to 13.91 M USD, representing a 14,090.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Clearside Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clearside Biomedical

All Key Metrics — Clearside Biomedical